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Abstract
Background: Hedgehog (HH) signaling is critical for the expansion of granule neuron precursors (GNPs) within the
external granular layer (EGL) during cerebellar development. Aberrant HH signaling within GNPs is thought to give rise
to medulloblastoma (MB) - the most commonly-observed form of malignant pediatric brain tumor. Evidence in both
invertebrates and vertebrates indicates that cyclic AMP-dependent protein kinase A (PKA) antagonizes HH signalling.
Receptors specific for the neuropeptide pituitary adenylyl cyclase activating polypeptide (PACAP, gene name ADCYAP1)
are expressed in GNPs. PACAP has been shown to protect GNPs from apoptosis in vitro, and to interact with HH
signaling to regulate GNP proliferation. PACAP/ptch1 double mutant mice exhibit an increased incidence of MB
compared to ptch1 mice, indicating that PACAP may regulate HH pathway-mediated MB pathogenesis.
Methods: Primary MB tumorsphere cultures were prepared from thirteen ptch1
+/-/p53
+/- double mutant mice and
treated with the smoothened (SMO) agonist purmorphamine, the SMO antagonist SANT-1, the neuropeptide
PACAP, the PKA activator forskolin, and the PKA inhibitor H89. Gene expression of gli1 and [
3H]-thymidine
incorporation were assessed to determine drug effects on HH pathway activity and proliferation, respectively. PKA
activity was determined in cell extracts by Western blotting using a phospho-PKA substrate antibody.
Results: Primary tumor cells cultured for 1-week under serum-free conditions grew as tumorspheres and were
found to express PAC1 receptor transcripts. Gli1 gene expression was significantly reduced by SANT-1, PACAP and
forskolin, but was unaffected by purmorphamine. The attenuation of gli1 gene expression by PACAP was reversed
by the PKA inhibitor H89, which also blocked PKA activation. Treatment of tumorsphere cultures with PACAP,
forskolin, and SANT-1 for 24 or 48 hours reduced proliferation.
Conclusions: Primary tumorspheres derived from ptch1
+/-/p53
+/- mice exhibit constitutive HH pathway activity.
PACAP antagonizes HH signalling in these cells in a manner blocked by the PKA antagonist H89. PACAP and
pharmacological activation of PKA also inhibited proliferation. Our data suggests that regulation of HH signaling by
PACAP/PKA signaling may provide an alternative to SMO inhibition for the treatment of MB.
Background
Medulloblastoma (MB) is a malignant pediatric brain
tumor that is thought to arise in many cases from trans-
formation of granule neuron precursors (GNPs) within
the external granular layer (EGL) of the developing
cerebellum reviewed in [1]. Medulloblastoma is classified
into the following subtypes based on their phenotypic [2]
and genetic characteristics [3]: classic, large cell, anaplas-
tic, desmoplastic and MB with extensive nodularity. Ana-
lyses of human desmoplastic MB samples revealed
altered activity of, and/or mutations in, molecules of the
sonic hedgehog (HH) signaling pathway including
patched-1 (ptch1)a n dglioma-associated oncogene homo-
log 1 (gli-1) [1,3-5]. HH signaling is pivotal in the
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stem cell self-renewal [9] and MB pathogenesis [4,5,10],
and has also been implicated in a variety of additional
human cancers including lung, pancreatic, and prostate
reviewed in [11]. Mutations in ptch1 (the gene that codes
for the Patched-1 12 pass transmembrane protein, a
negative regulator of the HH signaling cascade), are
observed with Gorlin’s (Basal Cell Nevus) Syndrome - an
autosomal hereditary disease characterized by the devel-
opment of MB, basal cell carcinomas, and rhabdomyosar-
coma [12,13]. Ptch1
-/- mice die in utero while ptch1
+/-
mice typically survive but develop cerebellar tumors clo-
sely resembling MB in about 15% of the cases [10].
Our present understanding of the HH signaling cas-
cade suggests that binding of the hedgehog ligands to
PTCH-1 de-represses smoothened (SMO), allowing for
the cascade of events leading to the activation of cubitus
interruptus (Ci) in flies and the Gli transcription factors
in vertebrates reviewed in [14,17]. The Gli transcription
factors bind to the promoters of several genes consid-
ered to be HH targets (including gli1 and ptch1)
[16-19]. Presently, molecules that act directly on compo-
nents of the canonical HH pathway, including several
that target SMO, are in various stages of clinical trials
[20]. On the other hand, the protein kinase A (PKA) sig-
nalling pathway is known to antagonize hedgehog (HH)
signaling in both invertebrates [21] and vertebrates
[22,23], suggesting an alternative approach to blocking
overactive HH activity. Nonetheless, little is know about
the significance of the PKA/HH interaction in the
pathogenesis of MB and other tumors.
PACAP is a 38-amino-acid peptide originally identified
on the basis of its ability to induce production of cAMP
in pituitary cells [24]. PACAP regulates a variety of bio-
logical functions including neuroblast proliferation
[25,26], and neuroblast survival [27]. In the developing
brain PACAP binds to, and signals through, the G-
protein coupled receptor PAC1, increasing cAMP pro-
duction and PKA activity [28]. PAC1 is also coupled to
other signaling cascades in some cells, including phos-
pholipase C (PLC) [29], phosphatidylinositol 3-Kinase
(PI3-K) [30], src [31], and the MAP kinase pathways
[32-34].
Gene transcripts for the HH targets genes ptch1 and
gli1 are expressed within the EGL in the developing rat
and mouse cerebella [26,35], indicating that the HH
pathway is active in these cells. PAC1 gene transcripts
are also present in the EGL [26], suggesting that the
PACAP and HH pathways might interact within the
proliferating cells in this layer. Moreover, the robust
proliferative action of SHH on cultured GNPs was com-
pletely blocked by either treatment with PACAP or
pharmacological induction of cAMP/PKA [26]. The
potential significance of a PACAP/HH interaction in
MB was recently demonstrated. First, PAC1 gene tran-
scripts were found to be abundantly expressed in MB
preneoplastic lesions in ptch1 mutant mice [36]. Second,
deletion of a single copy of PACAP in ptch1
+/- mutant
mice was found to increase the incidence of MB approxi-
mately 2.5 fold [36]. Taken together, these data suggest
that PACAP may regulate HH signaling in MB patho-
genesis. In this work we investigate the interaction
between HH and PACAP/PKA signaling in murine pri-
mary tumorspheres derived from MB tumors arising in
ptch1
+/-/p53
+/- double mutant mice. Our data suggests
that regulation of HH signaling by PACAP/PKA may
provide a novel alternative to SMO inhibition for the
treatment of medulloblastoma (MB).
Methods
Animal Generation, Care, and Assessment of
Medulloblastoma
These studies utilized mice with single copy mutations
in both the ptch1 and the p53 genes. The creation of
these mice has been reported previously [10,37]. Gen-
eration of ptch1
+/-/p53
+/- mice were achieved by cross-
ing p53
-/- and ptch1
+/- mice as previously described by
Wetmore, Eberhart and Curran, 2001 [38]. Mice were
housed according to UCLA Institutional Guidelines,
including standard light-dark cycles with food and water
ad libitum. All mice were monitored daily for evidence
of tumor presence or illness.
Drugs and Stock Concentrations
PACAP-38, SANT-1 (a HH pathway antagonist), pur-
morphamine (a HH pathway agonist), and H-89 (a PKA
antagonist) were obtained from Calbiochem. DMSO
(vehicle) and forskolin (a cAMP/PKA inducer) were
obtained from Sigma. Treatment concentrations for the
drugs, unless otherwise stated, were as follows: 10 nM
PACAP, 5 μM forskolin, 3 μM purmorphamine, 1 μM
SANT-1 and 30 μM H89. When DMSO was used as
drug solvent its concentration was adjusted to 0.25% (v/
v) for all samples, except for experiments where H89
was used, in which case the final DMSO concentration
was adjusted to 0.55%. In all experiments using H89,
cells were pre-treated with this agent 30 minutes prior
to addition of other drugs.
Isolation of Primary Tumorspheres, Maintenance, and
Treatment
GNP-like tumor cells were isolated in a manner similar
to that of Zhao, H et al., 2008 [39]. A total of thirteen
individual tumor isolations and preparations were per-
formed. Briefly, tumors were minced in 1 mL of trypsin/
DNAse, placed into 1.5 mL eppendorf tubes and centri-
fuged at 750 × g for 5 min at 4°C. Pellets were resus-
pended in 800 μL of cold DNAse and immediately
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turation with a 200 μL pipet, and lastly with a fire
polished Pasteur pipet. After another centrifugation as
above, 500 μL of DNAse was added to the pellet with a
trituration. This sample was resuspended in 4.5 ml of
D M E M - F 1 2a n da p p l i e dt oa4 0μms t r a i n e r( B DF a l -
con). The cell suspension was carefully layered on top
of a 32%/60% percoll gradient and centrifuged at 2985 ×
g for 20 min at 4°C. Cells collected from the layer
between the 32% and 60% percoll were washed once
with cold DMEM-F12 by centrifuging at 2985 × g for 10
min. The supernatant was aspirated and the resulting
pellet was resuspended in serum free medium compris-
ing of DMEM/F12 medium (Invitrogen), Heparin [2 μg/
mL](Sigma), Penicillin/Streptomycin/Glutamine [1%]
(Invitrogen), bFGF [0.2 μg/mL] (Peprotech), EGF [0.02
μg/mL](Sigma), and B27 supplement [1:50] (Invitrogen).
The cells were then counted and plated into 6-well
plates containing 2 mL of medium such that the final
cell concentrations were either 1 × 10
6 cells/mL or 0.5
×1 0
6 cells/mL. Cells were then cultured for 6 or 7 days.
During this period the cells were supplemented with
additional bFGF (0.05 μg) and EGF (0.04 μg) on days 3
and 5. On day 6 or 7, serum-free media was added
when necessary to equalize all volumes at 2 mL, and
then drug treatments were added to the cells in the
same wells as indicated in the figure legends.
RNA Extraction and RT-PCR
Tumorspheres were pelleted in 1.5 mL eppendorf tube
by microcentrifugation (750 × g for 5 minutes at 4°C).
RNA was extracted from the samples using the TRIzol
reagent (Invitrogen) according to manufacturer’s
instructions. cDNA was generated using the iScript
cDNA synthesis kit (BioRad). Semi-quantitative RT-PCR
for pac1 and SYBR-Green quantitative real-time RT-
PCR for gapdh and gli1 were performed as described
previously [26,36]. Individual sample differences were
calculated based on the ratio of standard quantities of
gli1 and gapdh transcripts determined by the standard
curve method.
Western Blotting
Whole-cell lysates, prepared in NP-40 lysis buffer along
with 1 mM PMSF, 1 μg/ml each of aprotinin, leupeptin,
and pepstatin, 1 mM Na3VO4, 1 mM NaF (Sigma), were
analyzed by immunoblotting. Equal amounts of proteins
from whole-cell extracts were resolved on sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to PVDF membranes. The mem-
branes were subjected to Western blot analysis with
rabbit anti-phospho-PKA substrate antibody (1:2000;
Cell Signaling Technology) or mouse anti-b-actin anti-
body (1:5000; Cell Signaling Technology). The signals
f r o mt h ep r i m a r ya n t i b o d yw e r ea m p l i f i e db yh o r s e r a d -
ish peroxidase-conjugated goat anti-rabbit or anti-mouse
immunoglobulin G (Santa Cruz Biotechnology) and
detected with enhanced chemiluminescence (GE
Healthcare).
Proliferation Studies
Thymidine incorporation in tumorsphere cultures was
performed using the trichloroacetic acid (TCA) precipi-
tation method. Dissociated cells isolated from tumors by
percoll gradient as described above, were seeded in 12-
well tissue culture plates at the initial density of 1×10
6
cells/well and cultured in serum free media as indicated
above. After 24 hours, the tumorspheres were treated
for either 24 or 48 hours with indicated drugs. [
3H]-thy-
midine (NEN/PerkinElmer), 2 μCi/well, was added to
the wells during the last 18 hours of treatment. Tumor-
spheres were harvested and centrifuged at 800 × g for
10 min at 4°C. After removal of the supernatant, the
pellets were washed twice with 1 mL of PBS then lysed
in 500 μl of NaOH (0.5 M) for 10 minutes at room tem-
perature. Cell extracts were transferred into fresh tubes
and DNA was precipitated with 500 μl of cold 20%
TCA on ice for 20 min. The samples were centrifuged
at 20,000 × g for 20 min at 4°C. Supernatants were aspi-
rated and the DNA-containing pellets washed with 500
μl of 10% TCA. After a 10 min centrifugation, pellets
were finally reconstituted in 500 μlo f0 . 1MN a O Ha n d
transferred into scintillation vials. Incorporated radioac-
tivity was counted on a scintillation counter (Beckman)
using Aquasafe™ scintillation cocktail (Wallac).
Statistics
Statistical analyses were performed using the GraphPad
Prism 4.0 software. All P values were calculated using
Student’s t-test for comparison between two samples
only, and ANOVA followed by Bonferroni’s post hoc
test for multiple comparisons. A value of P <0 . 0 5w a s
considered significant. All data were normalized to vehi-
cle controls.
Results
Primary Mouse Medulloblastoma Cells Grow as
Tumorspheres and Exhibit Constitutive Hedgehog
Pathway Activity
Cell lines derived from human or murine MB tumors
have been used to understand the biology of MB, but
recent evidence indicate that propagated MB cell lines
lose much or all of their responsiveness to HH pathway
antagonism [40]. We therefore harvested fresh primary
MB tumor cells for each experiment. We utilized ptch1
+/-/p53
+/- double mutant mice for our studies because
mutations in the p53 tumor suppressor gene in the con-
text of ptch1 haploinsufficiency results in a higher
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tion alone [38]. Tumor cells were harvested and purified
by percoll gradient, and single cell suspensions were pla-
ted in serum-free media for 1 week using a modification
of methods reported by others to preserve HH pathway-
dependent proliferation [39]. After several days of cul-
ture the cells formed aggregates of increasing size,
referred to as “tumorspheres” (Figure 1A). To determine
if the HH pathway was active in these cells, we treated
these cultures at the end of the 1-week period with the
HH pathway antagonist SANT-1 (a known inhibitor of
smoothened (SMO), 1 μM [41]) and measured the
expression of the HH target gene gli1 by real time RT-
PCR. SANT-1 significantly decreased gli1 expression
(Figure 1B) relative to vehicle. These data implied that
the HH pathway is constitutively active in tumorsphere
cultures generated using our experimental paradigm.
To determine if the HH pathway could be activated
beyond basal levels in these tumorsphere cultures, we
treated them with the SMO agonist purmorphamine at
a concentration (3 μM) shown to induce maximum HH
signalling without cellular toxicity [42-44]. Purmorpha-
mine failed to induce gli1 expression above control
levels, suggesting that the HH pathway was already
maximally activated in the tumorspheres under these
experimental conditions (Figure 1C).
Pituitary adenylyl cyclase activating polypeptide (PACAP)
and Forskolin Inhibit Hedgehog Pathway Activity in
Primary Tumorspheres
Because the HH pathway exhibited a significant level of
constitutive activity in primary tumorsphere cultures, we
investigated if this activity could be inhibited by either
PACAP (10 nM) or forskolin (5 μM), an activator of
adenylyl cyclase. We first performed RT-PCR analysis
for the PACAP receptor PAC1 and confirmed that its
gene expression is preserved in tumorspheres cultures
(Figure 2B). Treatment with 10 nM PACAP and 5 μM
Figure 1 Primary Medulloblastoma Cells Form Tumorspheres and Exhibit Constitutive Hedgehog Pathway Activity.( A)Primary
medulloblastoma cells from ptch1
+/-/p53
+/- mice cultured in a serum-free environment formed tumorsphere-like aggregates within 24 hours,
which became progressively larger at three and five days.(B and C) Quantitative real time RT-PCR analysis of gli1 gene expression in 6-7 day old
tumorsphere cultures treated for 6 h with either the smoothened antagonist SANT-1 (1 μM) (B) or the smoothened agonist purmorphamine
(3 μM) (C) Gene expression experiments were performed at least three times and with at least n = 3 samples for each treatment. (**P < 0.01).
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in these cultures compared to vehicle treated controls
(Figure 2A).
Attenuation of Gli1 Expression in Primary Tumorspheres
by PACAP was Associated with PKA Activation and was
Reversed by the PKA Inhibitor H89
As both PACAP and forskolin typically exert their effects
in a PKA dependent manner, we investigated if their
effects could be reversed by the PKA inhibitor H89. To
confirm their effects on PKA activity, we performed Wes-
tern blot analyses using an antibody that detects proteins
containing a phospho-serine/threonine residue with argi-
nine at the -3 and -2 positions, which are typically found
on proteins phosphorylated by PKA. We observed that
treatment of primary tumorspheres with either 10 nM
PACAP or 5 μM forskolin induced similar increases in
PKA activity (Figure 3A) compared to vehicle treated
controls. Treatment with H89 (30 μM) reversed the
inductions of PKA activity by these treatments (Figure
3A). Moreover, treatment with H89 reversed the reduc-
tion in gli1 expression by 10 nM PACAP (Figure 3B).
These data indicate that PACAP attenuates HH signaling
in primary tumorspheres, most likely via a PKA depen-
dent mechanism.
PACAP and Forskolin Inhibit Cellular Proliferation in
Primary Tumorspheres
The above studies suggest that PACAP treatment or sti-
mulation of PKA activity by other methods might pro-
vide strategies to inhibit the growth of MB tumors. We
thus investigated the effects of PACAP (10 nM) and
forskolin (5 μM) on cellular proliferation using [
3H]-thy-
midine to measure DNA synthesis. As predicted, prolif-
eration was reduced by 24 or 48 hour treatment with
PACAP in a dose dependent manner. Forskolin (5 μM)
and SANT-1 (1 μM), also decreased proliferation at
these time periods (Figures. 4A and 4B). These data sug-
gest that PACAP and PKA activation might provide
therapeutic alternatives to SMO antagonism in the treat-
ment of MB.
Figure 2 PACAP and Forskolin Inhibit HH pathway activity in
Primary Tumorspheres.( A) Expression of the HH target gene gli1
in 6-7 day old primary tumorspheres treated for 6 hours with either
vehicle, 10 nM PACAP, 5 μM forskolin, or 1 μM SANT-1, determined
by real time RT-PCR. Experiments were performed three times with
at least n = 3 for each treatment (*P < 0.05, **P < 0.01). (B) RT-PCR
analysis demonstrating gene expression of the PAC1 PACAP
receptor in primary tumorspheres. Total brain (left lane) was used as
a positive control. Negative controls (lower panel) utilized the same
samples, but were not subjected to reverse transcriptase (RT).
Figure 3 Attenuation of Gli1 Expression in Primary Tumorspheres
by PACAP was Associated with PKA Activation and was Reversed
by the PKA Inhibitor H89.( A) Western blot analysis of PKA activity in
tumorsphere cultures treated with vehicle, 10 nM PACAP, 5 μM
forskolin, 30 μM H89, 10 nM PACAP plus 30 μM H89 or 5 μMf o r s k o l i n
plus 30 μM H89. Blot was incubated with a rabbit phospho-PKA-
substrate antibody (top) or a mouse b-actin antibody (bottom). The
blot shown is representative of 3 experiments. (B) Gli1 gene expression
in primary tumorspheres treated with either vehicle, 10 nM PACAP,
30 μM H89, or the combination of PACAP and H89. Experiments were
performed at least 3 times and with at least n = 3 for each treatment
(***P < 0.001).
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A large and diverse array of cancer types show evidence of
overactive HH signalling [11]. This has triggered an inten-
sive search for agents that selectively inhibit this pathway
[20]. As a result, several molecules have been discovered
or designed that directly interact and inhibit the activity of
SMO, some of which are in clinical trials [20]. Despite the
promise of this approach, two potential problems are that
1) some tumors acquire mutations in SMO that render
them relatively resistant to SMO antagonists [45], and 2)
SMO is critically involved in the growth of bones and
other tissues [11,46], and appears to regulate stem cell
biology [9] and [47]. Thus, there is a need for molecules
that act downstream of SMO in the HH signalling path-
way and that inhibit HH signalling specifically in tumor
cells. PKA is thought to act in the HH pathway down-
stream of SMO, phosphorylating and triggering proteo-
some-mediated degradation of Gli2 and Gli3 [48,50]. Thus
PKA activators might be expected to block HH signalling
even in the context of drug-resistant SMO mutations.
However, given that PKA is used in so many biological
processes, it is unlikely that general activation of PKA will
be useful as a treatment strategy. An alternative strategy
would be to activate PKA specifically in tumor cells. This
could potentially be achieved by targeting appropriate het-
erotrimeric G protein-coupled receptors expressed on the
cells. The data reported here suggest that a potentially-
effective strategy to treat MB tumors exhibiting overactive
HH signaling would be to activate PACAP receptors.
We investigated this possibility by using genetically engi-
neered mice that spontaneously develop MB, and a tissue
culture system that preserves a significant level of consti-
tutive HH activity in tumor cells. We found that PACAP
inhibited proliferation and the expression of the HH target
gene gli1 in these cells. Moreover, the reduction of gli1
gene expression by PACAP was reversed by PKA inhibi-
tion, and was mimicked by stimulation of the cAMP/PKA
p a t h w a yb yf o r s k o l i n .O v e r a l l ,t h ed a t as u g g e s tt h a t
PACAP, via activation of PKA, inhibits HH signalling and
HH-driven proliferation in MB cells. However, our find-
ings do not rule out alternative mechanisms of PACAP/
PKA action in these assays. For example, despite its action
on gli1 in MB tumorspheres, the ability of PACAP to inhi-
bit proliferation might be unrelated to its effects in HH
pathway activity. In this respect, PACAP (and PKA activa-
tion in general) is known on inhibit the proliferation of
manytypes ofcells [51,53], some ofwhich mightnot exhibit
HH pathway activity. In any case, the findings reported here
suggest that PACAP or PAC1 agonists could be useful as
alternatives to, or in conjunction with, SMO antagonists,
for the treatment ofMBand other HH dependent tumors.
Conclusions
Primary murine medulloblastoma derived tumorspheres
from ptch1
+/-/p53
+/- mice, cultured in a serum-free envir-
onment, express the PACAP receptor PAC1, and exhibit
constitutive HH pathway activity as evidenced by sensitiv-
ity to HH pathway antagonist SANT-1. Treatment of
Figure 4 PACAP and Forskolin Inhibit Proliferation in Primary Tumorsphere Cultures.[
3H]-thymidine incorporation assays were performed
in cultures treated with vehicle, increasing concentrations of PACAP, 5 μM forskolin, or 1 μM SANT-1 for 24 hours (A) or 48 hours (B). In each
case, [
3H]-thymidine was added for the last 18 hr of the experiment. Experiment was performed three times, with 3-4 samples for each
treatment (** P < 0.01, *** P < 0.001).
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forskolin significantly reduces gli1 expression in a manner
that is reversed by the PKA inhibitor H89. PACAP and
forskolin also block tumorsphere proliferation. These find-
ing suggest that PACAP or PKA activation may be useful
for therapeutic intervention in the treatment of MB.
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